Premium
Ulipristal acetate shows promise for treatment of PMDD
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30702
Subject(s) - irritability , ulipristal acetate , premenstrual dysphoric disorder , medicine , placebo , psychiatry , anxiety , alternative medicine , hormone , menstrual cycle , research methodology , population , environmental health , pathology , family planning
Women with premenstrual dysphoric disorder (PMDD) who received ulipristal acetate in a placebo‐controlled trial experienced improvement on a range of symptoms that included irritability and depression. Half of the participants receiving ulipristal acetate in the trial achieved full remission, the researchers reported.